Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA: 2010-2025

Historic EBITDA for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -$17.5 million.

  • Heron Therapeutics' EBITDA fell 264.46% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 51.24%. This contributed to the annual value of -$13.6 million for FY2024, which is 87.71% up from last year.
  • Per Heron Therapeutics' latest filing, its EBITDA stood at -$17.5 million for Q3 2025, which was down 634.12% from -$2.4 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' EBITDA peaked at $3.6 million during Q4 2024, and registered a low of -$63.9 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was -$9.2 million (2024), whereas its average is -$12.9 million.
  • The largest annual percentage gain for Heron Therapeutics' EBITDA in the last 5 years was 182.51% (2025), contrasted with its biggest fall of 264.46% (2025).
  • Over the past 5 years, Heron Therapeutics' EBITDA (Quarterly) stood at -$54.6 million in 2021, then skyrocketed by 63.71% to -$19.8 million in 2022, then spiked by 45.99% to -$10.7 million in 2023, then surged by 133.95% to $3.6 million in 2024, then tumbled by 264.46% to -$17.5 million in 2025.
  • Its EBITDA stands at -$17.5 million for Q3 2025, versus -$2.4 million for Q2 2025 and $2.6 million for Q1 2025.